| Abstract: |
Surgery is fundamental to curative treatment of lung cancer. Resectability is determined by patient fitness to undergo surgery and tumor characteristics. Appropriate tumor staging, especially mediastinal nodal involvement, is a critical aspect of surgical planning. Pulmonary function testing must be performed to determine whether a patient can tolerate loss of lung parenchyma safely. Stage I/II disease is treated definitively with lobectomy, with adjuvant chemotherapy for select patient groups, and sublobar resection is reserved for patients with high morbidities or low-risk tumors. Stage III disease has heterogeneous presentation, and careful evaluation must be performed to determine which patients will receive oncologic benefit from surgical intervention. © 2024 Elsevier Inc. All rights reserved. |
